TCON - トラコン・ファ―マシュ―ティカルズ (TRACON Pharmaceuticals Inc.)

TCONのニュース

   TRACON Pharmaceuticals to Present at the Jefferies Healthcare Conference  2022/06/02 12:05:00 GlobeNewswire
SAN DIEGO, June 02, 2022 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (Nasdaq: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and utilizing a cost efficient, CRO-independent product development platform to partner with life science companies through a profit-share, revenue share, or franchise model, today announced that Charles Theuer, M.D., Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the Jefferies Healthcare Conference on Friday, June 10, 2022 at 11:00 am Eastern Time.
   TRACON Pharmaceuticals, Inc. (TCON) CEO Charles Theuer on Q1 2022 Results - Earnings Call Transcript  2022/05/12 03:36:02 Seeking Alpha
TRACON Pharmaceuticals, Inc. (NASDAQ:NASDAQ:TCON) Q1 2022 Earnings Conference Call May 11, 2022 4:30 PM ET Company Participants Charles Theuer – President and Chief Executive Officer Scott…
   Tracon GAAP EPS of -$0.48 misses by $0.06  2022/05/11 20:09:53 Seeking Alpha
Tracon press release (TCON): Q1 GAAP EPS of -$0.48 misses by $0.06.Cash, cash equivalents and short-term investments were $16.6 million at March 31, 2022, compared to $24.1 million…
   TRACON Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update  2022/05/11 20:02:00 GlobeNewswire
SAN DIEGO, May 11, 2022 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (Nasdaq:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and utilizing a cost efficient, CRO-independent product development platform to partner with companies to develop and commercialize innovative products in the U.S., today announced financial results for the first quarter ended March 31, 2022. The Company will host a conference call and webcast today at 4:30 PM Eastern Time / 1:30 PM Pacific Time.
   3 Stocks Under $2 Insiders Are Buying  2022/05/11 12:08:26 Benzinga
US crude oil futures traded higher on Wednesday. Investors, meanwhile, focused on some notable insider trades. When insiders purchase or sell shares, it indicates their confidence or concern around the company''s prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision. Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga''s insider transactions platform.3 TRACON Pharmaceuticals The Trade: TRACON Pharmaceuticals, Inc. (NASDAQ: TCON ) President and CEO Charles Theuer acquired a total of 2,500 shares at an average price of $1.97. To acquire these shares, … Full story available on Benzinga.com
   TRACON Pharmaceuticals to Present at the BTIG Virtual Biotechnology Conference  2021/08/03 12:05:00 Intrado Digital Media
SAN DIEGO, Aug. 03, 2021 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and utilizing a cost efficient, CRO-independent product development platform to partner with ex-U.S. companies to develop and commercialize innovative products in the U.S., today announced that Charles Theuer, M.D., Ph.D., President and Chief Executive Officer, will present a corporate overview at the BTIG Virtual Biotechnology Conference on August 10, 2021 at 12:00pm Eastern Time.
   TRACON to Report Second Quarter 2021 Financial Results and Company Highlights on August 11, 2021  2021/07/28 12:05:00 Intrado Digital Media
SAN DIEGO, July 28, 2021 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and utilizing a cost efficient, CRO-independent product development platform to partner with ex-U.S. companies to develop and commercialize innovative products in the U.S., announced today that it will report its second quarter 2021 financial and operating results after the close of U.S. financial markets on Wednesday, August 11, 2021. In addition, management will host a conference call to provide an update on corporate activities and discuss the financial results.
   TRACON Pharmaceuticals Increases Previously Announced Bought Deal Offering of Common Stock to $15.0 Million  2021/07/22 02:30:00 Intrado Digital Media
SAN DIEGO, July 21, 2021 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ: TCON) (TRACON or the Company), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics, today announced that, due to demand, the underwriter has agreed to increase the size of the previously announced public offering and purchase on a firm commitment basis 3,926,702 shares of common stock of the Company at a price to the public of $3.82 per share, less underwriting discounts and commissions. In addition, the Company has granted the underwriter a 30-day option to purchase up to an additional 589,005 shares of common stock at the public offering price, less underwriting discounts and commissions. The closing of the public offering is expected to occur on or about July 26, 2021, subject to satisfaction of customary closing conditions.
   TRACON Pharmaceuticals Announces $10 Million Bought Deal Offering of Common Stock  2021/07/21 21:27:00 Intrado Digital Media
SAN DIEGO, July 21, 2021 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ: TCON) (TRACON or the Company), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics, today announced that it has entered into an underwriting agreement with H.C. Wainwright & Co. under which the underwriter has agreed to purchase on a firm commitment basis 2,617,802 shares of the Companys common stock at a public offering price of $3.82 per share, less underwriting discounts and commissions. In addition, the Company has granted the underwriter a 30-day option to purchase up to an additional 392,670 shares of common stock at the public offering price, less underwriting discounts and commissions. The offering is expected to close on or about July 26, 2021, subject to satisfaction of customary closing conditions.
   TRACON Pharmaceuticals Announces Appointment of Brenda Marczi, PharmD, as Senior Vice President, Regulatory Affairs, and Granting of Inducement Award  2021/07/20 12:05:00 Intrado Digital Media
SAN DIEGO, July 20, 2021 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and utilizing a cost efficient, CRO-independent product development platform to partner with ex-U.S. companies to develop and commercialize innovative products in the U.S., announced today the appointment of Brenda Marczi, PharmD, as Senior Vice President, Regulatory Affairs, and the granting of an inducement equity award to Dr. Marczi.
   TRACON Pharmaceuticals Announces Orphan Drug Designation  2021/07/03 12:52:48 Intrado Digital Media
TRACON Pharmaceuticals Announces Orphan Drug Designation GlobeNewswire
   Is TRACON Pharmaceuticals Inc (TCON) A Good Stock To Buy?  2021/07/02 13:29:11 Yahoo Finance
Is TRACON Pharmaceuticals Inc (TCON) A Good Stock To Buy? Yahoo Finance
   TRACON Pharmaceuticals Announces Appointment of Ya Huang as Executive Director of Statistical Programming and Granting of Inducement Award  2021/06/30 12:05:00 Intrado Digital Media
SAN DIEGO, June 30, 2021 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and utilizing a cost efficient, CRO-independent product development platform to partner with ex-U.S. companies to develop and commercialize innovative products in the U.S., announced today the appointment of Ya Huang as Executive Director of Statistical Programming and the grant of an inducement equity award to Mr. Huang.
   Subcutaneously Injected PD-L1 Antibody Envafolimab (KN035) Obtained Its Second Orphan Drug Designation From The U.S. FDA  2021/06/30 00:55:00 PR Newswire Asia (English)
SUZHOU, China , June 30, 2021 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to envafolimab (KN035), a recombinant humanized PD-L1 single-domain antibody independently invented by Alphamab Oncology, for the treatment of patients with soft tissue sarcoma. This is the second Orphan Drug Designation for Envafolimab after its first ODD in advanced biliary tract cancer and fourth ODD that Alphamab Oncology has obtained from the U.S. FDA. The Orphan Drug Act was passed in 1983 and Orphan Drug Designation is granted by the U.S. FDA to drugs or biologics intended to treat a rare disease or condition, defined as one that affects fewer than 200,000 people in the United States . Programs with Orphan Drug status receive partial tax credit for clinical trial expenditures, waived user fees and eligibility for seven years of marketing exclusivity. Obtaining the Orphan Drug Designation is of great significance for accelerating the development and marketing of new drugs.
   TRACON Pharmaceuticals Announces Orphan Drug Designation for Envafolimab in Soft Tissue Sarcoma  2021/06/29 12:05:00 Intrado Digital Media
Application Included Clinical Trial Data from Soft Tissue Sarcoma Patients Treated with Envafolimab in Phase 1 Trials

calendar